At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ABSI Absci Corporation.
Trading 01-10 14:32:08 EST
2.92
-0.30
-9.47%
High3.08
Low2.81
Vol7.49M
Open3.07
D1 Closing3.22
Amplitude8.39%
Mkt Cap334.80M
Tradable Cap251.98M
Total Shares114.86M
T/O21.63M
T/O Rate8.66%
Tradable Shares86.44M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Absci Partners With Owkin to Develop Immuno-oncology Treatment Candidates
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics using generative AI; with AstraZeneca PLC for AI-driven drug discovery against an oncology target; and with Twist Bioscience Corporation to design a novel therapeutic using generative AI. The company was founded in 2011 and is headquartered in Vancouver, Washington.